Tag:
Epogen
Latest Headlines
Latest Headlines
Amgen loses Supreme Court ruling in shareholder suit
Amgen was accused last month of getting special favors from lawmakers. Today the U.S. Supreme Court ruled against it in a securities case that sets precedent for the industry and beyond.
Affymax explores manufacturing for ties to fatal drug reactions
Drugmakers Affymax and Takeda are investigating whether manufacturing is playing a role in the allergic reactions that have resulted in three deaths and led it to recall all of its anemia drug Omontys from the market.
Amgen to whack 160 jobs
Amgen's earnings last week were not half bad. But they were not good enough to save the jobs of 160 employees whom the company says it will let go.
Amgen's Sensipar scored pricing shield from Congress
Congress didn't just head off the fiscal cliff with its compromise bill. It rescued Amgen ($AMGN) from Medicare price restraints on Sensipar, an oral treatment for kidney patients, at least temporarily.
Takeda, Affymax nail supply deal for Omontys anemia drug
Takeda Pharmaceuticals and Affymax ($AFFY) have sewn up another supply deal for their anemia drug Omontys. DSI Renal, one of the largest dialysis providers in the U.S., agreed to adopt Omontys to treat their patients with chronic kidney disease.
Falling Epogen sales crash on Amgen plant
Falling sales of Amgen's ($AMGN) anemia drug Epogen have come home to roost in Longmont, CO, where the company will idle the facility where the drug is made in bulk.
Did anemia drug giants game the system to rake in billions?
Amgen's big-selling anemia drugs were first brought in for questioning a few years ago. Studies and side-effect reports cast doubt on their safety. The FDA started a review.
Amgen pushes agenda for biosimilars on the FDA
The Thousand Oaks, CA-base drugmaker is one of 30 organizations on the docket today for the FDA's informal stakeholder meeting to discuss regulation of biosimilars.
Amgen founding CEO George Rathmann dies at 84
In the years after he took the helm of the company, Rathmann helped steer the development of Epogen and Neupogen. Only now does Amgen face rivals to its anemia franchise.
Affymax banks $50M milestone on ESA drug approval
Affymax has banked a $50 million check from its partner Takeda after they won FDA approval for an anemia treatment that will now compete with Amgen for market share.
